Alpha Teknova
Alpha Teknova's revenue rose 7.3% to $40 million in fiscal 2025. Its operating margin was −41.9%, up from −69.3% a year earlier. Free cash flow was −$10 million. The diluted share count rose 14.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Alpha Teknova lost money in fiscal 2025: a net loss of $17 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 88 | 42 | 28 | 30 | 21 |
| Debt incl. finance leases | 12 | 22 | 13 | 9 | 13 |
| Net debt (negative means net cash) | −76 | −20 | −15 | −21 | −8 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.2x | 0.1x | 0.1x | 0.2x |
| Interest coverage | −29.0x | −491.7x | −20.3x | −16.9x | −11.6x |
| Current ratio | 13.1x | 5.6x | 5.1x | 3.8x | 4.6x |
| Quick ratio | 12.4x | 4.5x | 3.8x | 3.2x | 3.6x |
Cash flow
Projections
Project Alpha Teknova's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $143,500 of Alpha Teknova shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | Matthew LowellChief Financial Officer | Bought | 40,000 | $2.19 | $87,600 | Form 4 |
| Mar 6, 2026 | Stephen GunstreamPresident and CEO, Director | Bought | 26,000 | $2.15 | $55,900 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 5 of 9 |
| Rule of 40 | −84.3% | −32.9% | −16.8% |
| Altman Z'' | 0.14 | −0.61 | −1.59 |
| Accruals ratio | −12.8% | −11.6% | −7.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 9 | 4 of 9 | 5 of 9 |
Compare
Put Alpha Teknova side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alpha Teknova | FY25 | 7.3% | −41.9% | −24.2% | −22.0% | — | 5 | |
| Rapid Micro Biosystems | FY25 | 19.7% | −141.1% | −95.0% | −192.8% | — | 2 | Compare |
| MaxCyte | FY25 | −14.5% | −157.1% | −109.5% | — | — | — | Compare |
| Bionano Genomics | FY25 | −7.4% | −117.0% | −57.3% | −89.9% | — | 5 | Compare |
| Precipio | FY25 | 29.8% | −5.0% | 1.5% | −7.8% | −37.4x | 7 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 31 | 37 | 41 | 37 | 38 | 40 |
| Revenue growth | — | 17.9% | 12.3% | −11.4% | 2.9% | 7.3% |
| Gross profit | 18 | 18 | 18 | 10 | 7 | 13 |
| Research and development | 2 | 4 | 8 | 6 | 3 | 2 |
| Operating income | 5 | −12 | −50 | −36 | −26 | −17 |
| Net income | 4 | −10 | −48 | −37 | −27 | −17 |
| Diluted EPS (US$) | 0.16 | −0.61 | −1.69 | −1.16 | −0.57 | −0.32 |
| Diluted shares (millions) | 4 | 16 | 28 | 32 | 47 | 54 |
| Cash flow | ||||||
| Cash from operations | 2 | −9 | −27 | −19 | −12 | −9 |
| Capital expenditure | 6 | 20 | 28 | 8 | 1 | 1 |
| Free cash flow | −3 | −29 | −56 | −27 | −14 | −10 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 4 | 4 | 4 | 3 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 5 | 88 | 42 | 28 | 30 | 21 |
| Debt incl. finance leases | 0 | 12 | 22 | 13 | 9 | 13 |
| Total assets | 63 | 166 | 152 | 129 | 119 | 104 |
| Total liabilities | 10 | 23 | 52 | 39 | 36 | 35 |
| Shareholders' equity | 17 | 143 | 100 | 90 | 82 | 69 |
| Margins and ratios | ||||||
| Gross margin | 56.7% | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% |
| Operating margin | 14.9% | −32.5% | −119.9% | −96.9% | −69.3% | −41.9% |
| Net margin | 11.4% | −26.6% | −114.6% | −100.3% | −70.9% | −42.6% |
| Free cash flow margin | −9.5% | −78.5% | −134.1% | −72.9% | −35.8% | −24.2% |
| Rule of 40 (growth + FCF margin) | — | −60.6% | −121.8% | −84.3% | −32.9% | −16.8% |
| Return on capital | — | −24.0% | −53.3% | −36.4% | −30.3% | −22.0% |
| Return on equity | — | −12.3% | −39.0% | −38.7% | −31.0% | −22.8% |
| Return on assets | — | −8.6% | −29.8% | −26.2% | −21.6% | −15.5% |
| Net debt to EBITDA | −0.8x | — | — | — | — | — |